Craig M. Pratt, M.D., Joins NewCardio’s Scientific Advisory Board

SAN JOSE, Calif.--(BUSINESS WIRE)--NewCardio, Inc. (OTC BB: NWCI), a cardiac diagnostic and services company, today announced that Craig M. Pratt, M.D., has agreed to join the Company’s Scientific Advisory Board.

Dr. Pratt joins NewCardio with a long and impressive record as a leader in cardiovascular medicine, with a proven track record in more than a dozen clinical trials and as a key advisor to the U.S. Food and Drug Administration. Dr. Pratt is a Fellow in the American College of Cardiology and a member of the American Heart Association, Heart Rhythm Society, American College of Physicians and the International Society of Heart Failure. He has been the principal investigator for numerous trials of drug and device investigations for the treatment of arrhythmias, heart failure, ischemia and other cardiovascular disorders. These include over 10 national trials with the National Heart, Lung, and Blood Institute (NHLBI) including the Beta Blocker Heart Attack Trial (BHAT), the Cardiac Arrhythmia Pilot Study (CAPS), Thrombolysis in Myocardial Infarction (TIMI I, II), Studies of Left Ventricular Dysfunction (SOLVD), Comparison of Electrophysiologic Study to Electrocardiographic Monitoring (ESVEM), Cardiac Arrhythmia Suppression Trial (CAST), Asymptomatic Cardiac Ischemia Pilot (ACIP), Antiarrhythmic Drugs Versus Defibrillators (AVID) and the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) trials.

Dr. Pratt has served as a member of the Cardiovascular and Renal Drugs Advisory Board of the Food and Drug Administration (FDA) for 11 years, including Chairman of the Cardio-Renal Advisory Board from 1987-1993. He continues to serve as a consultant to the FDA’s Center for Drug Evaluation and Research and serves on numerous national and international clinical trial committees as chairman and as a member of data safety monitoring board, event committees, steering committees and writing committees.

Dr. Pratt received a Bachelor of Science degree in Zoology from the University of California, Los Angeles, and a Doctorate of Medicine from the University of California, Irvine. He completed his post-graduate training in internal medicine and cardiology at the University of California, Davis. He served as a medical officer in the U.S. Navy during the Vietnam War, and played a major role in the care of Vietnamese refugees at Camp Pendleton Marine Base, California. Dr. Pratt joined the faculty of Baylor College of Medicine in 1978 where he remained until September 2005 as Professor of Medicine in the Section of Cardiology. He is currently Professor of Medicine at Weill Cornell Medical College, Director of Research for the Methodist DeBakey Heart Center and Director of the Coronary Intensive Care Unit at The Methodist Hospital in Houston, Texas.

Branislav Vajdic, Ph.D., chief executive officer of NewCardio, Inc., commented, “Dr. Pratt is an internationally renowned cardiologist with a proven background in advancing ECG applications and investigating the cardiac impact of pharmaceuticals, including an esteemed tenure as a key advisor to the highest levels of the FDA. Adding his experience and expertise to our scientific advisory board speaks to the opportunity NewCardio’s 3D ECG technology platform provides. As we develop and advance our technology, Dr. Pratt will prove invaluable as both a world-class practicing cardiologist and a leader in cardiac-related clinical trials. We welcome Dr. Pratt to our team.”

About NewCardio, Inc.

NewCardio is a cardiac diagnostic and services company focused on the development of a proprietary platform technology to provide dramatically higher accuracy to, and thus significantly increase the value of, the standard 12-lead electrocardiogram (ECG). NewCardio’s development-stage software and hardware products and services are intended to improve the diagnosis and monitoring of cardiovascular disease (CVD), as well as cardiac safety assessment of drugs under development. The company’s three-dimensional ECG platform is designed to reduce the time and expense involved in assessing cardiac status while increasing the ability to diagnose clinically significant conditions which were previously difficult to detect. NewCardio intends to initially compete in two large segments of the CVD diagnostic market: cardiac safety in drug development and diagnostics. For more information, visit www.newcardio.com.

Forward-Looking Statements

This press release contains forward-looking statements within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than those that are purely historical are forward-looking statements. Words such as “expect,” “anticipate,” “believe,” “estimate,” “intend,” “plan,” and similar expressions also identify forward-looking statements. Forward-looking statements include, without limitation, statements regarding the development of the company’s proprietary technology platform and its products, the timing of such development and the timing and results of clinical trials and regulatory review. All statements in this press release other than those that are purely historical are forward-looking statements. Such statements reflect management’s current views, are based on certain assumptions and involve risks and uncertainties.

There are important factors that could cause the company’s actual results to differ materially from those in the forward-looking statements. These factors, include, without limitation, the following: the company’s ability to develop its technology platform and its products; the risk that the company will not be able to develop the technology platform and products in the current projected timeframe; the risk that the products will not achieve performance standards in clinical trials; the risk that the clinical trial process will take longer than projected; the risk that the products will not receive regulatory approval; the risk that the regulatory review process will take longer than projected; the company’s ability to commercialize its products; any of which could impact sales, costs and expenses and/or planned strategies. Additional information regarding factors that could cause results to differ can be found in the company’s most recent filings with the U.S. Securities and Exchange Commission (the “SEC”), including, without limitation, its current report on Form 8-K/A filed with the SEC on January 22, 2008.

These forward-looking statements are based on information as of March 25, 2008, and the company assumes no obligation to publicly update or revise its forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized.